Therapeutic targeting of immune checkpoints has garnered significant attention in the area
of cancer immunotherapy, in which efforts have focused in particular on cytotoxic T …

Both animal models and human observational and genetic studies have shown that immune
and inflammatory mechanisms play a key role in hypertension and its complications. We …

The long-term management of maintenance immunosuppression in kidney transplant
recipients remains complex. The vast majority of patients are treated with the calcineurin …

Donor-specific HLA antibodies (DSA) have a negative impact on kidney graft survival.
Therefore, we analyzed the occurrence of DSA and antibody-mediated rejection (AMR) in …

Background Most people who receive a kidney transplant die from either cardiovascular
disease or cancer before their transplant fails. The most common reason for someone with a …

Belatacept, a T cell costimulation blocker, demonstrated superior renal function, lower
cardiovascular risk, and improved graft and patient survival in renal transplant recipients …

Delayed graft function (DGF) remains a major barrier to improved outcomes after kidney
transplantation. High‐risk transplant recipients can be identified, but no definitive prediction …

Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and
steroids. Belatacept is a less toxic CNI alternative, but existing regimens rely on steroids and …

For kidney transplant recipients, immunosuppression commonly consists of combination
treatment with a calcineurin inhibitor, an antiproliferative agent and a corticosteroid. Many …

Kidney hypoperfusion during episodes of systemic hypotension or after surgical
procurement for transplantation can lead to tubular cell death via necrosis and apoptosis …